MDXH · MDxHealth SA
$0.40
-0.01 (-2.63%)
At close · Jul 29
Market Cap
$21.11M
Shares
51.36M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.41
Open$0.41
Day$0.41–0.43
52W$0.40–5.33
Avg vol 30d587K
Short int956K · 1.9% float · 1.4d
Short vol47%
Last earningsMar 31, 2026
DataNov 2021–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−84%
below
Price vs 50-day avg
−26%
below
RSI (14)
33
neutral
MACD trend
Positive
52-week position
0%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
−89%
trailing
YTD return
−88%
this year
Relative strength
−96%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Distributing
7 of 52 funds reported for Jun 30 · net -97.5K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.86% of float · ▲ +2794.0% MoM · 1.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
52 holders — mid 2-yr range
Squeeze score
49
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−92%
past year
ATR
9.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
2026 revenue guidance for our core cancer business, excluding Re
· 2026
Initiated
$110M – $115M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−84%
Bearish
Price vs 50-day avg
−26%
Bearish
RSI (14)
33
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Distributing
7 of 52 funds reported for Jun 30 · net -97.5K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.86% of float · ▲ +2794.0% MoM · 1.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
52 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 0%
52-wk high $5
vs 200-day avg -84%
vs 50-day avg -26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MDXH
this stock
MDxHealth SA
|
$21.11M | -88.5% | — | — | 1.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$214.21B | -0.4% | +0.4% | 31.7 | 1.4% |
|
DHR
Danaher Corp /De/
|
$139.93B | -12.7% | +8.5% | 35.3 | 1.4% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.93B | -15.8% | +10.4% | 41.9 | 2.7% |
|
IQV
Iqvia Holdings Inc.
|
$40.55B | +7.8% | +41.6% | 30.2 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MDXH | -2.8% | 0.0% | -88.6% | +0.0% | -88.5% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -1.9% | +0.0% | -96.0% | +0.8% | -97.1% |